Abstract
Fifty-seven patients with advanced prostate cancer resistant to first-line hormonal therapy were treated with estramustine and additionally randomized for treatment with clodronate or placebo. Clodronate treatment was started with 5 days intravenous administration (300 mg day[-1]) and followed by oral treatment (1.6 g day[-1]) for 12 months. Skeletal pain relief was only about 10% better in the clodronate than in the placebo group. The results do not support the superiority of combined intravenous and oral treatment with clodronate compared with oral administration only.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kylmälä, T., Taube, T., Tammela, T. et al. Concomitant i.v. and oral clodronate in the relief of bone pain – a double-blind placebo-controlled study in patients with prostate cancer. Br J Cancer 76, 939–942 (1997). https://doi.org/10.1038/bjc.1997.488
Issue Date:
DOI: https://doi.org/10.1038/bjc.1997.488
This article is cited by
-
Patienten mit ossär metastasiertem Prostatakarzinom: Können Bisphosphonate helfen?
Der Urologe (2019)
-
Radiological changes following second-line zoledronic acid treatment in breast cancer patients with bone metastases
Clinical & Experimental Metastasis (2009)
-
The role of bisphosphonates in the management of prostate cancer
Current Oncology Reports (2006)
-
The role of bisphosphonates in hormone-refractory prostate cancer
World Journal of Urology (2005)
-
Advances in the use of bisphosphonates in the prostate cancer setting
Prostate Cancer and Prostatic Diseases (2004)